New study tracks Ngenla's Long-Term safety in kids with growth deficiency
NCT ID NCT05602766
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 29 times
Summary
This study looks at the long-term safety and effects of Ngenla, a medicine already approved for children with growth hormone deficiency. One child will be followed from their first dose until November 2027. Researchers will monitor side effects, growth rate, and blood sugar levels to see how well the treatment works over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROWTH HORMONE DEFICIENCY WITHOUT EPIPHYSEAL CLOSURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.